Autolus Therapeutics plc (AUTL) News
Follow Autolus Therapeutics plc (AUTL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Autolus Therapeutics to Report Third-Quarter 2026 Results November 10
Autolus Therapeutics says it will report third-quarter 2026 financial results and host a conference call on November 10, 2026.
EQUITY | Oct 26, 2026, 08:19 PM UTC
L
Autolus gets FDA RMAT designation for obe-cel in lupus
Autolus Therapeutics says FDA has granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis. Enrollment in LUMINA, its pivotal Phase 2 study in refractory lupus nephritis, is ongoing.
REGULATION | Sep 09, 2026, 11:03 AM UTC
M
Autolus Therapeutics gets FDA RMAT designation for obe-cel in lupus
Autolus Therapeutics says the FDA granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis.
REGULATION | Sep 09, 2026, 11:00 AM UTC
L
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est
Autolus Therapeutics (NASDAQ: AUTL ) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
EARNINGS | Aug 11, 2026, 11:01 AM UTC
L
AUTL - Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
AUTL - Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
EARNINGS | Aug 03, 2026, 08:06 PM UTC
H
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Monday. Shares of CNH Industrial NV (NYSE: CNH ) rose sharply during Monday’s session after the company reported better-than-expected second-
EARNINGS | Aug 03, 2026, 02:00 PM UTC
L
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 — $150 million, from $120 — $135 m
EARNINGS | Aug 03, 2026, 11:20 AM UTC
H
Autolus Therapeutics Reports Q2 Revenue
Autolus Therapeutics reports preliminary Q2 revenue
EQUITY | Aug 03, 2026, 11:13 AM UTC